Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Alumis Inc. Common StockNASDAQ: ALMS

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares of 127.69M shares rose 67.0% year over year, behind the +93.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at +384.0% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +67.0% toward the trailing-twelve-month pace of +93.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
127.69M+2.1% QoQ
Last fiscal yearDec 2025
850.3M+2900.2% YoY
LTMJun 2026
115.39M+93.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+67.0%——
1 year+2900.2%——
3-year CAGR+384.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
850.3M USD
Year-over-year change
+2900.2%
3-year CAGR
+384.0%

Weighted Avg Shares vs competitors

How ALMS compares with its peers on the latest reported figures

  • ALMS's LTM Jun 2026 weighted avg shares of 115.39M shares is the 2nd highest of the 10 companies compared; the peer median is 36.24M shares.
  • Its year-over-year change of +93.7% is the 2nd highest of 10, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +384.0% compares with a peer median of +8.4%.
ALMS Competitors Peer median
Weighted Avg Shares for ALMS and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.7%+384.0%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
TLSATiziana Life Sciences LtdFY202559.14M +10.9%+5.2%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ALMS) 36.24M+2.4%+8.4%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.